Oxidative stress cytoprotection reagent

MOTS-c Peptide Introduction and Overview

This research-grade peptide is supplied exclusively for laboratory and experimental use. MOTS-C is examined in experimental models investigating mitochondrial signaling, cellular energy regulation, and metabolic adaptation. Research interest centers on how cells respond to energetic stress and efficiency-related signals.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid peptide encoded by the mitochondrial genome (mtDNA). Discovered in 2015, it functions as a mitochondrial-derived peptide (MDP) with systemic regulatory roles. Unlike traditional mitochondrial proteins, MOTS-c translocates from mitochondria to the nucleus, influencing gene expression and metabolic pathways. Its molecular-level mechanism of action (MoA) centers on modulating cellular energy homeostasis, primarily through AMPK activation and purine metabolism interference. Recent studies (2025-2026) highlight its potential in metabolic disorders, aging, and neurodegeneration, with applications as an exercise mimetic. Structurally distinct from other MDPs like Humanin (a 24-amino acid peptide), MOTS-c shares cytoprotective effects but targets different pathways, making it promising for neurodegenerative diseases such as Alzheimer's and Parkinson's.

Core Molecular Mechanism

At the molecular level, MOTS-c regulates metabolism by inhibiting the folate/methionine cycle in the nucleus. It binds to nuclear factors, reducing de novo purine biosynthesis, which leads to accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). AICAR is a potent activator of AMP-activated protein kinase (AMPK), mimicking energy stress and triggering catabolic pathways.

• Glycolysis Enhancement and AICAR Buildup: MOTS-c promotes glycolysis by shifting cellular reliance from oxidative phosphorylation (OXPHOS) to glycolytic flux under stress. This is achieved via AICAR-mediated AMPK activation, which phosphorylates targets like ACC (acetyl-CoA carboxylase), inhibiting fatty acid synthesis and favoring glucose uptake.
• Recent studies (e.g., 2025 Nature article) confirm MOTS-c's role in pancreatic islets, where it boosts glycolytic enzymes like PFK1, preventing senescence.
• NAD+ Improvement and AMPK Synergy: MOTS-c elevates NAD+ levels by enhancing NAD+ salvage pathways and mitochondrial biogenesis via PGC-1α upregulation. Although AMPK activation typically depletes NAD+ in acute states, MOTS-c's chronic effects parallel NAD+ boosting (e.g., via SIRT1 activation), resolving the apparent paradox. This dual action supports mitochondrial repair and energy efficiency, as seen in 2025 NIH studies showing restored OXPHOS and reduced ATP hydrolysis in damaged mitochondria.
• p53 Upregulation and NF-κB Downregulation: MOTS-c translocates to the nucleus, interacting with transcription factors to increase p53 expression, promoting DNA repair and apoptosis in stressed cells. Conversely, it suppresses NF-κB signaling, reducing pro-inflammatory cytokines like TNF-α and CRP. This anti-inflammatory profile is key for metabolic health, without elevating homocysteine or other markers, despite increased methylation (via methionine cycle modulation).
• Mitochondrial Damage Repair: MOTS-c improves mitochondrial function by increasing ROS in a controlled manner ( hormesis), enhancing OXPHOS capacity, and mitigating damage from aging or diabetes. 2025